Insulin aspart, recombinant Subcutaneous and Sinemet 100/25
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Sinemet 100/25 and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: carbidopa / levodopa
Brand name: Parcopa, Rytary, Sinemet, Sinemet CR, Duopa
Synonyms: Carbidopa and levodopa, Carbidopa and Levodopa
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Sinemet 25-100
- Insulin aspart, recombinant Subcutaneous-Sinemet 25-250
- Insulin aspart, recombinant Subcutaneous-Sinemet 250/25
- Insulin aspart, recombinant Subcutaneous-Sinemet CR
- Insulin aspart, recombinant Subcutaneous-Sinemet CR 100/25
- Insulin aspart, recombinant Subcutaneous-Sinemet CR 200/50
- Sinemet 100/25-Insulin degludec
- Sinemet 100/25-Insulin Degludec (U-100) Prefilled Pens
- Sinemet 100/25-Insulin Degludec (U-100) Vials
- Sinemet 100/25-Insulin Degludec (U-200) Prefilled Pens
- Sinemet 100/25-Insulin degludec and liraglutide
- Sinemet 100/25-Insulin degludec and liraglutide Subcutaneous